Increased alveolar concentration of nitric oxide is related to serum-induced lung fibroblast proliferation in patients with systemic sclerosis

Journal of Rheumatology

Volumn 37, Issue 8, 2010, Pages 1680-1687

  Hua Huy, Thong ^a   Tiev, Kiet Phong ^b   Chéreau, Christiane ^a   Duong Quy, Sy ^a   Cabane, Jean ^b   Dinh Xuan, Anh Tuan ^a  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b UNIVERSITÉ PARIS EST   (France)

Author keywords

Alveolitis; Interstitial lung disease; Myofibroblast; Nitric oxide; Systemic sclerosis

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; BROXURIDINE; NITRIC OXIDE;

ADULT; ARTICLE; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; INFLAMMATION; INTERSTITIAL LUNG DISEASE; LUNG ALVEOLITIS; LUNG ALVEOLUS; LUNG FIBROBLAST; MALE; MYOFIBROBLAST; PRIORITY JOURNAL; PROTEIN EXPRESSION; RESPIRATORY TRACT INFLAMMATION; SERUM; SYSTEMIC SCLEROSIS;

ACTINS; ADULT; BLOOD PROTEINS; BROMODEOXYURIDINE; CELL DIFFERENTIATION; CELL LINE; CELL PROLIFERATION; CELLS, CULTURED; FEMALE; FIBROBLASTS; HUMANS; MALE; MIDDLE AGED; MYOCYTES, SMOOTH MUSCLE; NITRIC OXIDE; PROSPECTIVE STUDIES; PULMONARY ALVEOLI; PULMONARY FIBROSIS; SCLERODERMA, SYSTEMIC; SERUM;

EID: 77955484680     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: 10.3899/jrheum.090915     Document Type: Article

References (31)

1. Steen VD, Medsger TA Jr. Severe organ involvement in systemic sclerosis with diffuse scleroderma. Arthritis Rheum 2000;43:2437-44.
2. Jimenez SA, Derk CT. Following the molecular pathways toward an understanding of the pathogenesis of systemic sclerosis. Ann Intern Med 2004;140:37-50.
3. Steen VD, Medsger TA. Changes in causes of death in systemic sclerosis, 1972-2002. Ann Rheum Dis 2007;66:940-4.
4. Varga J, Abraham D. Systemic sclerosis: a prototypic multisystem fibrotic disorder. J Clin Invest 2007;117:557-67.
5. Bouros D, Wells AU, Nicholson AG, Colby TV, Polychronopoulos V, Pantelidis P, et al. Histopathologic subsets of fibrosing alveolitis in patients with systemic sclerosis and their relationship to outcome. Am J Respir Crit Care Med 2002;165:1581-6.
6. Dinh-Xuan AT. Endothelial modulation of pulmonary vascular tone. Eur Respir J 1992;5:757-62.
7. Paredi P, Kharitonov SA, Loukides S, Pantelidis P, du Bois RM, Barnes PJ. Exhaled nitric oxide is increased in active fibrosing alveolitis. Chest 1999;115:1352-6.
8. Bryckaert M, Fontenay M, Liote F, Bellucci S, Carriou R, Tobelem G. Increased mitogenic activity of scleroderma serum: inhibitory effect of human recombinant interferon-gamma. Ann Rheum Dis 1994;53:776-9.
9. Baroni SS, Santillo M, Bevilacqua F, Luchetti M, Spadoni T, Mancini M, et al. Stimulatory autoantibodies to the PDGF receptor in systemic sclerosis. N Engl J Med 2006;354:2667-76.
10. Romanska HM, Polak JM, Coleman RA, James RS, Harmer DW, Allen JC, et al. iNOS gene upregulation is associated with the early proliferative response of human lung fibroblasts to cytokine stimulation. J Pathol 2002;197:372-9.
11. Tiev KP, Le-Dong NN, Duong-Quy S, Hua-Huy T, Cabane J, Dinh-Xuan AT. Exhaled nitric oxide, but not serum nitrite and nitrate, is a marker of interstitial lung disease in systemic sclerosis. Nitric Oxide 2009;20:200-6.
12. Fajac I, Kahan A, Menkes CJ, Dessanges JF, Dall'Ava-Santucci J, Dinh-Xuan AT. Increased nitric oxide in exhaled air in patients with systemic sclerosis. Clin Exp Rheumatol 1998;16:547-52.
13. Moodley YP, Lalloo UG. Exhaled nitric oxide is elevated in patients with progressive systemic sclerosis without interstitial lung disease. Chest 2001;119:1449-54.
14. Tiev KP, Cabane J, Aubourg F, Kettaneh A, Ziani M, Mouthon L, et al. Severity of scleroderma lung disease is related to alveolar concentration of nitric oxide. Eur Respir J 2007;30:26-30.
15. Girgis RE, Gugnani MK, Abrams J, Mayes MD. Partitioning of alveolar and conducting airway nitric oxide in scleroderma lung disease. Am J Respir Crit Care Med 2002;165:1587-91.
16. Servettaz A, Guilpain P, Goulvestre C, Chéreau C, Hercend C, Nicco C, et al. Radical oxygen species production induced by advanced oxidation protein products predicts clinical evolution and response to treatment in systemic sclerosis. Ann Rheum Dis 2007;66:1202-9.
17. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum 1980;23:581-90.
18. LeRoy EC, Black C, Fleischmajer R, Jablonska S, Krieg T, Medsger TA Jr, et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988;15:202-5.
19. Rolla G, Colagrande P, Scappaticci E, Chiavassa G, Dutto L, Cannizzo S, et al. Exhaled nitric oxide in systemic sclerosis: relationships with lung involvement and pulmonary hypertension. J Rheumatol 2000;27:1693-8.
20. ATS/ERS recommendations for standardized procedures for the online and offline measurement of exhaled lower respiratory nitric oxide and nasal nitric oxide, 2005. Am J Respir Crit Care Med 2005;171:912-30.
21. George SC, Hogman M, Permutt S, Silkoff PE. Modeling pulmonary nitric oxide exchange. J Appl Physiol 2004;96:831-9.
22. Tsoukias NM, George SC. A two-compartment model of pulmonary nitric oxide exchange dynamics. J Appl Physiol 1998;85:653-66.
23. Tiev KP, Coste J, Ziani M, Aubourg F, Cabane J, Dinh-Xuan AT. Diagnostic value of exhaled nitric oxide to detect interstitial lung disease in systemic sclerosis. Sarcoidosis Vasc Diffuse Lung Dis 2009;26:32-8.
24. Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, et al. Standardisation of spirometry. Eur Respir J 2005;26:319-38.
25. Mimura Y, Ihn H, Jinnin M, Asano Y, Yamane K, Tamaki K. Constitutive phosphorylation of focal adhesion kinase is involved in the myofibroblast differentiation of scleroderma fibroblasts. J Invest Dermatol 2005;124:886-92.
26. Jinnin M, Ihn H, Mimura Y, Asano Y, Yamane K, Tamaki K. Effects of hepatocyte growth factor on the expression of type I collagen and matrix metalloproteinase-1 in normal and scleroderma dermal fibroblasts. J Invest Dermatol 2005;124:324-30.
27. Wynn T. Cellular and molecular mechanisms of fibrosis. J Pathol 2008;214:199-210.
28. Xiang Y, Matsui T, Matsuo K, Shimada K, Tohma S, Nakamura H, et al. Comprehensive investigation of disease-specific short peptides in sera from patients with systemic sclerosis: complement C3f-des-arginine, detected predominantly in systemic sclerosis sera, enhances proliferation of vascular endothelial cells. Arthritis Rheum 2007;56:2018-30.
29. Strange C, Bolster MB, Roth MD, Silver RM, Theodore A, Goldin J, et al. Bronchoalveolar lavage and response to cyclophosphamide in scleroderma interstitial lung disease. Am J Respir Crit Care Med 2008;177:91-8.
30. Clements PJ, Goldin JG, Kleerup EC, Furst DE, Elashoff RM, Tashkin DP, et al. Regional differences in bronchoalveolar lavage and thoracic high-resolution computed tomography results in dyspneic patients with systemic sclerosis. Arthritis Rheum 2004;50:1909-17.
31. van der Lee I, Zanen P, Grutters JC, Snijder RJ, van den Bosch JM. Diffusing capacity for nitric oxide and carbon monoxide in patients with diffuse parenchymal lung disease and pulmonary arterial hypertension. Chest 2006;129:378-83.